Pdf/Clinicalguidance.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

Pdf/Clinicalguidance.Pdf A Peer-Reviewed Journal Tracking and Analyzing Disease Trends pages 191–360 EDITOR-IN-CHIEF D. Peter Drotman EDITORIAL STAFF EDITORIAL BOARD Dennis Alexander, Addlestone Surrey, United Kingdom Founding Editor Ban Allos, Nashville, Tennessee, USA Joseph E. McDade, Rome, Georgia, USA Michael Apicella, Iowa City, Iowa, USA Managing Senior Editor Barry J. Beaty, Ft. Collins, Colorado, USA Martin J. Blaser, New York, New York, USA Polyxeni Potter, Atlanta, Georgia, USA David Brandling-Bennet, Washington, D.C., USA Associate Editors Donald S. Burke, Baltimore, Maryland, USA Charles Ben Beard, Ft. Collins, Colorado, USA Jay C. Butler, Anchorage, Alaska David Bell, Atlanta, Georgia, USA Charles H. Calisher, Ft. Collins, Colorado, USA Arturo Casadevall, New York, New York, USA Patrice Courvalin, Paris, France Kenneth C. Castro, Atlanta, Georgia, USA Stephanie James, Bethesda, Maryland, USA Thomas Cleary, Houston, Texas, USA Brian W.J. Mahy, Atlanta, Georgia, USA Anne DeGroot, Providence, Rhode Island, USA Takeshi Kurata, Tokyo, Japan Vincent Deubel, Shanghai, China Martin I. Meltzer, Atlanta, Georgia, USA Ed Eitzen, Washington, D.C., USA Duane J. Gubler, Honolulu, Hawaii, USA David Morens, Bethesda, Maryland, USA Scott Halstead, Arlington, Virginia, USA J. Glenn Morris, Baltimore, Maryland, USA David L. Heymann, Geneva, Switzerland Tanja Popovic, Atlanta, Georgia, USA Sakae Inouye, Tokyo, Japan Patricia M. Quinlisk, Des Moines, Iowa, USA Charles King, Cleveland, Ohio, USA Keith Klugman, Atlanta, Georgia, USA Gabriel Rabinovich, Buenos Aires, Argentina S.K. Lam, Kuala Lumpur, Malaysia Didier Raoult, Marseilles, France Bruce R. Levin, Atlanta, Georgia, USA Pierre Rollin, Atlanta, Georgia, USA Myron Levine, Baltimore, Maryland, USA David Walker, Galveston, Texas, USA Stuart Levy, Boston, Massachusetts, USA John S. MacKenzie, Brisbane, Australia Henrik C. Wegener, Copenhagen, Denmark Tom Marrie, Edmonton, Alberta, Canada Copy Editors John E. McGowan, Jr., Atlanta, Georgia, USA Angie Frey, Ronnie Henry, Anne Mather, Carol Snarey, Stephen S. Morse, New York, New York, USA Cathy Young Philip P. Mortimer, London, United Kingdom Production Fred A. Murphy, Davis, California, USA Barbara E. Murray, Houston, Texas, USA Reginald Tucker, Ann Jordan, Maureen Marshall P. Keith Murray, Ames, Iowa, USA Editorial Assistant Stephen Ostroff, Atlanta, Georgia, USA Carolyn Collins Rosanna W. Peeling, Geneva, Switzerland David H. Persing, Seattle, Washington, USA Gianfranco Pezzino, Topeka, Kansas, USA www.cdc.gov/eid Richard Platt, Boston, Massachusetts, USA Mario Raviglione, Geneva, Switzerland Emerging Infectious Diseases Leslie Real, Atlanta, Georgia, USA Emerging Infectious Diseases is published monthly by the David Relman, Palo Alto, California, USA National Center for Infectious Diseases, Centers for Disease Nancy Rosenstein, Atlanta, Georgia, USA Control and Prevention, 1600 Clifton Road, Mailstop D61, Atlanta, GA 30333, USA. Telephone 404-371-5329, Connie Schmaljohn, Frederick, Maryland, USA fax 404-371-5449, email [email protected]. Tom Schwan, Hamilton, Montana, USA Ira Schwartz, Valhalla, New York, USA The opinions expressed by authors contributing to this journal Tom Shinnick, Atlanta, Georgia, USA do not necessarily reflect the opinions of the Centers for Disease Patricia Simone, Atlanta, Georgia, USA Control and Prevention or the institutions with which the authors Bonnie Smoak, Bethesda, Maryland, USA are affiliated. Rosemary Soave, New York, New York, USA P. Frederick Sparling, Chapel Hill, North Carolina, USA All material published in Emerging Infectious Diseases is in Jan Svoboda, Prague, Czech Republic the public domain and may be used and reprinted without special Bala Swaminathan, Atlanta, Georgia, USA permission; proper citation, however, is required. Robert Swanepoel, Johannesburg, South Africa Use of trade names is for identification only and does not Phillip Tarr, Seattle, Washington, USA imply endorsement by the Public Health Service or by the U.S. Timothy Tucker, Cape Town, South Africa Department of Health and Human Services. Elaine Tuomanen, Memphis, Tennessee, USA Mary E. Wilson, Cambridge, Massachusetts, USA ∞ Emerging Infectious Diseases is printed on acid-free paper that meets John Ward, Atlanta, Georgia, USA the requirements of ANSI/NISO 239.48-1992 (Permanence of Paper) Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 2, February 2005 A Peer-Reviewed Journal Tracking and Analyzing Disease Trends Vol. 11, No. 2, February 2005 On the Cover Novel Flavivirus or New Romare Bearden (1911–1988). Lineage of West Nile Virus . .225 The Sea Nymph (1977) T. Bakonyi et al. Collage on various papers with paint and Rabensburg virus, isolated from Culex pipiens graphite on fiberboard mosquitoes in central Europe, represents a new (111.8 cm x 81.3 cm). lineage of West Nile virus or a novel flavivirus of the Permanent collection: Glen and Lynn Tobias. Japanese encephalitis virus group. Cover art copyright Romare Bearden Foundation / Survey for Bat Lyssaviruses, Licensed by VAGA, New York, New York Thailand . .232 B. Lumlertdacha et al. About the Cover p. 358 Existence of lyssavirus infection in Thai bats has been confirmed by demonstration of serum neutralizing antibodies. Perspective p. 205 Distinguishing Febrile Respiratory Spotted Fever and Typhus Illnesses from SARS . .191 Group Rickettsioses . .237 K. Khan et al. Y.-J. Choi et al. Optimal management of febrile respiratory illnesses Multiplex nested PCR and sequencing analysis during a hypothetical SARS outbreak varies, but indicated rickettsialike agents in serum specimens increasing influenza vaccination rates would save from febrile patients. money and lives. Pneumocystis jirovecii in General Population . .245 Research F.J. Medrano et al. Human Disease from Influenza A P. jirovecii colonization can be frequently detected (H5N1), Thailand, 2004 . .201 in immunocompetent adults, which suggests that T. Chotpitayasunondh et al. the general population could be a source of this Direct contact with sick poultry, young age, infection. pneumonia and lymphopenia, and acute respiratory distress syndrome should prompt specific laboratory Cryptosporidiosis Decline after testing for H5 influenza. Membrane Filtration . .251 S. Goh et al. No H5N1 Transmission to Hospital Sporadic cryptosporidiosis and associated hospital Employees, Hanoi . .210 admissions of children declined after membrane N.T. Liem et al. filtration of public drinking water supplies was A seroprevalence study found no transmission of introduced. avian influenza H5N1 viruses from patients to hospital employees in Vietnam, 2004. Carbapenemase in Enterobacteriaceae, U.S. Rivers . .260 Bacterial Zoonoses and Infective C. Aubron et al. Endocarditis, Algeria . .216 Identification of imipenem-resistant Enterobacter A. Benslimani et al. asburiae isolates from distant rivers indicates an Serologic and molecular tools are important for the environmental reservoir for carbapenemase genes. diagnosis of blood culture–negative endocarditis. Investigation of Rickettsial Infection in Brazil . .265 p. 221 L.A. Sangioni et al. Surveys of horse serum are a useful method of surveillance for Brazilian spotted fever in areas where humans are exposed to Amblyomma cajennense ticks. Waddlia malaysiensis: New Chlamydialike Bacterium . .271 P.K.B. Chua et al. A Peer-Reviewed Journal Tracking and Analyzing Disease Trends Vol. 11, No. 2, February 2005 A novel obligate intracellular bacterium was isolated from urine samples from fruit bats (Eonycteris spelaea) in peninsular Malaysia. 330 Pneumocystis Transmission in Pediatric Transplant Unit Quarantine for SARS, Taiwan . .278 B. Höcker et al. Y.-H. Hsieh et al. Quarantine for SARS during the 2003 Taiwan outbreak expedited case detection, thereby Another Dimension indirectly preventing infections. 333 First Self Wild Animal Mortality Monitoring G. Callahan and Human Ebola . .283 P. Rouquet et al. An animal mortality monitoring network in Gabon Letters and the Republic of Congo has demonstrated potential to predict and possibly prevent human 339 Schistosoma mansoni in Family Ebola outbreaks. 5 Years after Safari p. 288 341 Methicillin-resistant Historical Review Staphylococcus aureus, Singapore Smallpox Surveillance and 343 Mumps Virus–associated Control Measures . .291 Hemophagocytic Syndrome E. Kerrod et al. 343 Imported Cutaneous Diphtheria, Targeted surveillance and containment Germany interventions have been successful for outbreak control and should be explored as alternatives to 344 Antimicrobial Drug Consumption mass vaccination. in Companion Animals Dispatches 346 Vibrio cholerae SXT Element, Laos 347 Impact of Influenza Pandemic on 298 In Vitro Host-Cell Susceptibility Pacific Islands to Usutu Virus 349 Mycotic Brain Abscess T. Bakonyi et al. 351 Tuberculosis in Undocumented 302 Bat Incidents at Children’s p. 299 Migrants, Geneva Camps, New York A. Robbins et al. 352 Mycobacterium chelonae in Kidney-Pancreas Recipient 306 West Nile Virus in Morocco I. Schuffenecker et al. 354 Psychological Effects of Quarantine (Replies) 310 Differential Detection of Multiple Respiratory Pathogens Book Reviews T. Briese et al. 314 Comparing Aberration 356 Community-based Health Research Detection Methods L. Hutwagner et al. 356 The Pneumococcus 317 Malaria Epidemic and Drug 357 DNA Amplification Resistance, Djibouti C. Rogier et al. News & Notes 322 Late Recognition of SARS in Nosocomial Outbreak About the Cover T. Wong et al. 358 Hazards of Travel 326 Typhoid Fever in Children in Urban Slum, Bangladesh
Recommended publications
  • Microbiology of Endodontic Infections
    Scient Open Journal of Dental and Oral Health Access Exploring the World of Science ISSN: 2369-4475 Short Communication Microbiology of Endodontic Infections This article was published in the following Scient Open Access Journal: Journal of Dental and Oral Health Received August 30, 2016; Accepted September 05, 2016; Published September 12, 2016 Harpreet Singh* Abstract Department of Conservative Dentistry & Endodontics, Gian Sagar Dental College, Patiala, Punjab, India Root canal system acts as a ‘privileged sanctuary’ for the growth and survival of endodontic microbiota. This is attributed to the special environment which the microbes get inside the root canals and several other associated factors. Although a variety of microbes have been isolated from the root canal system, bacteria are the most common ones found to be associated with Endodontic infections. This article gives an in-depth view of the microbiology involved in endodontic infections during its different stages. Keywords: Bacteria, Endodontic, Infection, Microbiology Introduction Microorganisms play an unequivocal role in infecting root canal system. Endodontic infections are different from the other oral infections in the fact that they occur in an environment which is closed to begin with since the root canal system is an enclosed one, surrounded by hard tissues all around [1,2]. Most of the diseases of dental pulp and periradicular tissues are associated with microorganisms [3]. Endodontic infections occur and progress when the root canal system gets exposed to the oral environment by one reason or the other and simultaneously when there is fall in the body’s immune when the ingress is from a carious lesion or a traumatic injury to the coronal tooth structure.response [4].However, To begin the with, issue the if notmicrobes taken arecare confined of, ultimately to the leadsintra-radicular to the egress region of pathogensIn total, and bacteria their by-productsdetected from from the the oral apical cavity foramen fall into to 13 the separate periradicular phyla, tissues.
    [Show full text]
  • Summary of National Advisory Committee on Immunization (Naci) Updates of July 2, 2021
    SUMMARY OF NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION (NACI) UPDATES OF JULY 2, 2021 MRNA COVID-19 VACCINES AND MYOCARDITIS On July 2, 2021, the Public Health Agency of Canada released updated advice from the National Advisory Committee on Immunization (NACI) on the use of mRNA COVID-19 vaccines. These recommendations are based on current scientific evidence and NACI's expert opinion. On June 30, 2021, Health Canada updated the product monographs, the documents that provide information for health care providers on the use of the vaccines, for the mRNA COVID-19 vaccines (Pfizer-BioNTech, Moderna) to include very rare reports of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart) following vaccination. In light of these changes, NACI is providing updated advice on second doses for individuals who experienced myocarditis and/or pericarditis after receiving a first dose of an mRNA vaccine. NACI continues to strongly recommend that a complete series with an mRNA vaccine should be offered to all eligible individuals without contraindications, including those 12 years of age and older. The Pfizer-BioNTech vaccine is approved for use in people 12 years and over and the Moderna vaccine is approved for use in people 18 years of age and over. NACI is now also recommending the following: Informed consent for people receiving an mRNA vaccine should include a discussion about the very rare risk of myocarditis and/or pericarditis following immunization. As a precaution, NACI recommends that individuals who experienced myocarditis and/or pericarditis after a first dose of an mRNA vaccine should wait to get their second dose until more information is available.
    [Show full text]
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • Skin and Soft Tissue Infections Ohsuerin Bonura, MD, MCR Oregon Health & Science University Objectives
    Difficult Skin and Soft tissue Infections OHSUErin Bonura, MD, MCR Oregon Health & Science University Objectives • Compare and contrast the epidemiology and clinical presentation of common skin and soft tissue diseases • State the management for skin and soft tissue infections OHSU• Differentiate true infection from infectious disease mimics of the skin Casey Casey is a 2 year old boy who presents with this rash. What is the best treatment? A. Soap and Water B. Ibuprofen, it will self OHSUresolve C. Dicloxacillin D. Mupirocin OHSUImpetigo Impetigo Epidemiology and Treatment OHSU Ellen Ellen is a 54 year old morbidly obese woman with DM, HTN and venous stasis who presented with a painful left leg and fever. She has had 3 episodes in the last 6 months. What do you recommend? A. Cefazolin followed by oral amoxicillin prophylaxis B. Vancomycin – this is likely OHSUMRSA C. Amoxicillin – this is likely erysipelas D. Clindamycin to cover staph and strep cellulitis Impetigo OHSUErysipelas Erysipelas Risk: lymphedema, stasis, obesity, paresis, DM, ETOH OHSURecurrence rate: 30% in 3 yrs Treatment: Penicillin Impetigo Erysipelas OHSUCellulitis Cellulitis • DEEPER than erysipelas • Microbiology: – 6-48hrs post op: think GAS… too early for staph (days in the making)! – Periorbital – Staph, Strep pneumoniae, GAS OHSU– Post Varicella - GAS – Skin popping – Staph + almost anything! Framework for Skin and Soft Tissue Infections (SSTIs) NONPurulent Purulent Necrotizing/Cellulitis/Erysipelas Furuncle/Carbuncle/Abscess Severe Moderate Mild Severe Moderate Mild I&D I&D I&D I&D IV Rx Oral Rx C&S C&S C&S C&S Vanc + Pip-tazo OHSUEmpiric IV Empiric MRSA Oral MRSA TMP/SMX Doxy What Are Your “Go-To” Oral Options For Non-Purulent SSTI? Amoxicillin Doxycycline OHSUCephalexin Doxycycline Trimethoprim-Sulfamethoxazole OHSU Miller LG, et al.
    [Show full text]
  • Western Gorilla Social Structure and Inter-Group Dynamics
    Western Gorilla Social Structure and Inter-Group Dynamics Robin Morrison Darwin College This dissertation is submitted for the degree of Doctor of Philosophy March 2019 Declaration of Originality This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as declared in the Preface and specified in the text. It is not substantially the same as any that I have submitted, or, is being concurrently submitted for a degree or diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. I further state that no substantial part of my dissertation has already been submitted, or, is being concurrently submitted for any such degree, diploma or other qualification at the University of Cambridge or any other University or similar institution except as declared in the Preface and specified in the text. Statement of Length The word count of this dissertation is 44,718 words excluding appendices and references. It does not exceed the prescribed word limit for the Archaeology and Anthropology Degree Committee. II Western Gorilla Social Structure and Inter-Group Dynamics Robin Morrison The study of western gorilla social behaviour has primarily focused on family groups, with research on inter-group interactions usually limited to the interactions of a small number of habituated groups or those taking place in a single location. Key reasons for this are the high investment of time and money required to habituate and monitor many groups simultaneously, and the difficulties of making observations on inter-group social interaction in dense tropical rainforest.
    [Show full text]
  • Antibiotic Use Guidelines for Companion Animal Practice (2Nd Edition) Iii
    ii Antibiotic Use Guidelines for Companion Animal Practice (2nd edition) iii Antibiotic Use Guidelines for Companion Animal Practice, 2nd edition Publisher: Companion Animal Group, Danish Veterinary Association, Peter Bangs Vej 30, 2000 Frederiksberg Authors of the guidelines: Lisbeth Rem Jessen (University of Copenhagen) Peter Damborg (University of Copenhagen) Anette Spohr (Evidensia Faxe Animal Hospital) Sandra Goericke-Pesch (University of Veterinary Medicine, Hannover) Rebecca Langhorn (University of Copenhagen) Geoffrey Houser (University of Copenhagen) Jakob Willesen (University of Copenhagen) Mette Schjærff (University of Copenhagen) Thomas Eriksen (University of Copenhagen) Tina Møller Sørensen (University of Copenhagen) Vibeke Frøkjær Jensen (DTU-VET) Flemming Obling (Greve) Luca Guardabassi (University of Copenhagen) Reproduction of extracts from these guidelines is only permitted in accordance with the agreement between the Ministry of Education and Copy-Dan. Danish copyright law restricts all other use without written permission of the publisher. Exception is granted for short excerpts for review purposes. iv Foreword The first edition of the Antibiotic Use Guidelines for Companion Animal Practice was published in autumn of 2012. The aim of the guidelines was to prevent increased antibiotic resistance. A questionnaire circulated to Danish veterinarians in 2015 (Jessen et al., DVT 10, 2016) indicated that the guidelines were well received, and particularly that active users had followed the recommendations. Despite a positive reception and the results of this survey, the actual quantity of antibiotics used is probably a better indicator of the effect of the first guidelines. Chapter two of these updated guidelines therefore details the pattern of developments in antibiotic use, as reported in DANMAP 2016 (www.danmap.org).
    [Show full text]
  • Coronavirus Fact Sheet
    CORONAVIRUS FACT SHEET The Assembly of First Nations (AFN) is providing this overview of the coronavirus, and information on resources in your region. As the situation is evolving rapidly, please visit the Public Health Agency of Canada and Indigenous Services Canada for the most updated information. Canada’s Chief Public Health Officer, Dr Theresa Tam, has assessed the public health risk of COVID-19 within Canada to be low. • Coronaviruses in general are part of a large family of viruses which may cause illness in people and in animals. Human coronaviruses are common and are typically associated with mild illnesses, like the common cold. • Coronavirus Disease 2019 (COVID-19) is a new disease that has not been previously identified in humans. • Currently there is NO vaccine to protect against 2019 novel coronavirus infection. • Those who are infected with COVID-19 may have little to no symptoms. You may not know you • The flu vaccine doesnot protect against have symptoms of COVID-19 because they are coronaviruses. similar to a cold or flu. • For now, there is no specific treatment. Most o Symptoms may take up to 14 days to appear people with the common coronavirus illness after exposure to COVID-19. This is the lon- will recover on their own and your health care gest known infectious period for this disease. provider may recommend steps you can take to relieve symptoms. o Symptoms have included fever, cough, difficulty breathing, pneumonia in both lungs. • Common prevention measures for viruses, such as the COVID-19 and influenza, include: • Coronavirus infections are diagnosed by a health care provider based on symptoms and confirmed o Regular hand washing with soap and warm through laboratory tests.
    [Show full text]
  • Covid-19: How Doctors and Healthcare Systems Are Tackling Coronavirus
    BMJ 2020;368:m1090 doi: 10.1136/bmj.m1090 (Published 18 March 2020) Page 1 of 5 Feature BMJ: first published as 10.1136/bmj.m1090 on 18 March 2020. Downloaded from FEATURE GLOBAL HEALTH Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide As coronavirus continues to spread, doctors and healthcare systems are facing a multitude of challenges at all stages of the pandemic Janice Hopkins Tanne 1, Erika Hayasaki 2, Mark Zastrow 3, Priyanka Pulla 4, Paul Smith 5, Acer Garcia Rada 6 1New York; 2Boston; 3Seoul; 4Bangalore; 5Sydney; 6Madrid United States least one site already open in the New York City suburb of New Rochelle, handling around 250 people a day. The United States declared a national emergency on 13 March The American Medical Association, which represents about as covid-19 spread to 49 of the country’s 50 states. half of US doctors, called the emergency declaration “necessary http://www.bmj.com/ President Donald Trump announced $50bn (£42.1bn; €45.6bn) to help ensure that America’s health system has sufficient to help combat the virus, as well as powers to waive laws and resources.” Meanwhile, some doctors complained that they did restrictions to make care more available, such as through not have test kits and were short of protective equipment. Other telehealth and allowing doctors to practise in states they are not physicians said that access to Medicaid, insurance for poor licensed in. patients, should be improved and sped up. The president—who has tested negative for covid-19 after At a 15 March press conference Anthony Fauci, head of the contact with an infected Brazilian official—said that many more National Institute of Allergy and Infectious Diseases, told the on 30 April 2020 by guest.
    [Show full text]
  • Pyoderma Gangrenosum in Myelodysplasia and Acute Leukaemia
    Postgrad Med J: first published as 10.1136/pgmj.61.718.689 on 1 August 1985. Downloaded from Postgraduate Medical Journal (1985) 61, 689-694 Pyoderma gangrenosum in myelodysplasia and acute leukaemia Peter Jacobs', S. Palmer2 and E.C. Gordon-Smith2 'The University ofCape Town Leukaemia Centre and the Department ofHaematology, Groote Schuur Hospital, Observatory, 7925, Cape Town, South Africa and 'The Department ofHaematology, Royal Postgraduate Medical School, London, UK. Summary: Pyoderma gangrenosum is a rare occurrence in patients with haematological malignancy. This characteristic but nonspecific inflammatory process with skin destruction occurred in 4 patients with myelodysplasia, in one with acute leukaemic transformation of myelofibrosis, and in de novo acute myeloblastic leukaemia in another. Clinically, the cutaneous lesion in these patients differed from that associated with inflammatory bowel disease, arthritis, or the idiopathic type ofpyoderma gangrenosum by having the vesiculo-bulious borders. Histopathological differences were also evident since more superficial layers ofthe skin were involved in the ulceration than typically encountered in patients with non-malignant systemic disease. Despite the less penetrating nature of this variant, treatment of the pyoderma gangrenosum is unsatisfactory and in the absence of effective therapy for the underlying disease, healing occurred only in the patient with acute leukaemia who achieved complete remission in response to chemotherapy. copyright. Introduction Pyoderma gangrenosum
    [Show full text]
  • Quantitative and Qualitative Analysis of Microorganisms in Root‑Filled Teeth with Persistent Infection: Monitoring of the Endodontic Retreatment
    Published online: 2019-09-26 Original Article Quantitative and qualitative analysis of microorganisms in root‑filled teeth with persistent infection: Monitoring of the endodontic retreatment Marcos S. Endo1, Caio C. R. Ferraz1, Alexandre A. Zaia1, Jose F. A. Almeida1, Brenda P. F. A. Gomes1 1Department of Restorative Dentistry, Endodontics Correspondence: Dr. Brenda PFA Gomes Division, Piracicaba Dental School – State University Email: [email protected] of Campinas – UNICAMP, Piracicaba, SP, Brazil ABSTRACT Objective: The aim of this study was to investigate in vivo microorganisms detected in root‑filled teeth with post‑treatment apical periodontitis and quantify colony‑forming units (CFU) during endodontic retreatment. Materials and Methods: Fifteen root‑filled teeth had their previous gutta‑percha removed and were randomly instrumented before being divided into three groups and medicated with either [Ca (OH) 2 + 2% CHX gel], [Ca (OH) 2 + 0.9% NaCl] or 2% CHX gel. Samples were taken after removal of gutta‑percha (S1), after chemomechanical preparation using 2% CHX gel (S2), and after inter‑appointment dressing (S3) for 7 or 14 days later. Cultivable bacteria recovered from infected root canals at the three stages were counted and identified by means of culture and PCR assay (16S rDNA). Quantitative data were statistically analyzed by using Mann‑Whitney test in which pairs of groups were compared (P < 0.05). Results: CFU counts decreased significantly from S1 to S2 (P < 0.05). No significant difference was found between S2 and S3 (P = 0.3093) for all three experimental groups. Chemomechanical preparation and intra‑canal dressing promoted significant median reductions of 99.61% and 99.57%, respectively, in the number of bacteria compared to S1 samples.
    [Show full text]
  • Integrating Taxonomic, Functional, and Strain-Level Profiling of Diverse
    TOOLS AND RESOURCES Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3 Francesco Beghini1†, Lauren J McIver2†, Aitor Blanco-Mı´guez1, Leonard Dubois1, Francesco Asnicar1, Sagun Maharjan2,3, Ana Mailyan2,3, Paolo Manghi1, Matthias Scholz4, Andrew Maltez Thomas1, Mireia Valles-Colomer1, George Weingart2,3, Yancong Zhang2,3, Moreno Zolfo1, Curtis Huttenhower2,3*, Eric A Franzosa2,3*, Nicola Segata1,5* 1Department CIBIO, University of Trento, Trento, Italy; 2Harvard T.H. Chan School of Public Health, Boston, United States; 3The Broad Institute of MIT and Harvard, Cambridge, United States; 4Department of Food Quality and Nutrition, Research and Innovation Center, Edmund Mach Foundation, San Michele all’Adige, Italy; 5IEO, European Institute of Oncology IRCCS, Milan, Italy Abstract Culture-independent analyses of microbial communities have progressed dramatically in the last decade, particularly due to advances in methods for biological profiling via shotgun metagenomics. Opportunities for improvement continue to accelerate, with greater access to multi-omics, microbial reference genomes, and strain-level diversity. To leverage these, we present bioBakery 3, a set of integrated, improved methods for taxonomic, strain-level, functional, and *For correspondence: phylogenetic profiling of metagenomes newly developed to build on the largest set of reference [email protected] (CH); sequences now available. Compared to current alternatives, MetaPhlAn 3 increases the accuracy of [email protected] (EAF); taxonomic profiling, and HUMAnN 3 improves that of functional potential and activity. These [email protected] (NS) methods detected novel disease-microbiome links in applications to CRC (1262 metagenomes) and †These authors contributed IBD (1635 metagenomes and 817 metatranscriptomes).
    [Show full text]
  • Chrysosporium Keratinophilum IFM 55160 (AB361656)Biorxiv Preprint 99 Aphanoascus Terreus CBS 504.63 (AJ439443) Doi
    bioRxiv preprint doi: https://doi.org/10.1101/591503; this version posted April 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Characterization of novel Chrysosporium morrisgordonii sp. nov., from bat white-nose syndrome (WNS) affected mines, northeastern United States Tao Zhang1, 2, Ping Ren1, 3, XiaoJiang Li1, Sudha Chaturvedi1, 4*, and Vishnu Chaturvedi1, 4* 1Mycology Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York, USA 2 Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China 3Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA 4Department of Biomedical Sciences, School of Public Health, University at Albany, Albany, New York, USA *Corresponding authors: Sudha Chaturvedi, [email protected]; Vishnu Chaturvedi, [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/591503; this version posted April 4, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Psychrotolerant hyphomycetes including unrecognized taxon are commonly found in bat hibernation sites in Upstate New York. During a mycobiome survey, a new fungal species, Chrysosporium morrisgordonii sp. nov., was isolated from bat White-nose syndrome (WNS) afflicted Graphite mine in Warren County, New York. This taxon was distinguished by its ability to grow at low temperature spectra from 6°C to 25°C. Conidia were tuberculate and thick-walled, globose to subglobose, unicellular, 3.5-4.6 µm ×3.5-4.6 µm, sessile or borne on narrow stalks.
    [Show full text]